AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown

AbbVie said it will buy Apogee Therapeutics for $10.9 billion in cash, a move that deepens its commitment to immunology rather than pushing it into a new therapeutic area.

The transaction values Apogee at $135.11 per share and comes with board approval from both companies, according to reporting on the deal. The companies expect the acquisition to close in the third quarter of 2026.

AbbVie shares rose after the announcement, while Apogee stock jumped sharply on the takeover news.

A bet on the same franchise

The acquisition is designed to reinforce the immunology business that has become AbbVie’s growth engine after Humira lost U.S. patent exclusivity in 2023. Since then, AbbVie has relied heavily on Skyrizi and Rinvoq to carry the franchise forward.

Rather than diversify away from that area, AbbVie is spending to protect and extend it. In reporting on the deal, CEO Robert Michael described the purchase as a way to expand the company’s immunology portfolio.

That makes the Apogee deal strategically simple: AbbVie is buying into the same broad inflammatory disease market it already treats as core to its future.

What Apogee brings

Apogee’s lead candidate is zumilokibart, a clinical-stage antibody being developed for atopic dermatitis and other inflammatory diseases. Some reporting also links the program to asthma, underscoring that AbbVie is acquiring a pipeline with more than one possible use case.

The appeal is not that Apogee opens a new category for AbbVie. It is that the asset fits cleanly alongside the company’s existing immunology strategy and could add another future growth driver in the same therapeutic lane.

AbbVie’s statement, as reported by multiple outlets, framed the deal as an expansion of its immunology portfolio and highlighted Apogee’s differentiated clinical-stage assets.

How the deal came together

Financial Times first reported the buyout on June 22, 2026, followed by more detailed reporting from Barron’s and Investor’s Business Daily later the same day.

Barron’s said the deal is all cash, priced at $135.11 per share, and expected to close in the third quarter of 2026. Subsequent coverage added market reaction and positioning context around the transaction.

The reported sequence matters because it shows how quickly the market and investors moved from reading the announcement as a headline number to treating it as a broader immunology strategy decision.

Why it matters

AbbVie is still working through the long shadow of Humira’s decline from biosimilar competition. The company has already leaned on Skyrizi and Rinvoq to soften that hit, and Apogee gives it another shot at preserving leadership in inflammatory disease.

The deal also signals that large drugmakers continue to prefer buying late-stage or clinical-stage assets over building entirely new franchises from scratch. In this case, AbbVie is paying up to keep its franchise concentrated where it already has scale.

Apogee investors, meanwhile, are getting a clean cash exit at a steep premium to the prior trading price.

What to watch next

The main near-term questions are execution, regulation, and development timing. The companies have said they expect to close in the third quarter, but formal filings will determine the final closing conditions and any breakup terms.

Investors will also watch for guidance on earnings dilution or accretion and for any update on how quickly zumilokibart and related programs can advance after the deal closes.

For now, the message from AbbVie is clear: it is paying to defend the immunology crown it built after Humira, not to move away from it.